Evidence map›Paper›PMID 38297807›Full record

ArticleAging cell2024

Human myofiber-enriched aging-induced lncRNA FRAIL1 promotes loss of skeletal muscle function.

Matthew J Miller, Kevin J Gries, George R Marcotte, Zachary Ryan, Matthew D Strub, Hawley E Kunz, Bonnie K Arendt, Surendra Dasari, Scott M Ebert, Christopher M Adams and 1 more

Open access · goldAbstract read
In one paragraph

Article in Aging cell, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Effects and Mechanisms of Long-TermFoods (Basel, Switzerland) · 2025
    Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Matthew J MillerDivision of Endocrinology, Mayo Clinic, Rochester, Minnesota, USA.
Kevin J GriesConcordia University of Wisconsin, Milwaukee, Wisconsin, USA.
George R MarcotteDivision of Endocrinology, Mayo Clinic, Rochester, Minnesota, USA.
Zachary RyanDivision of Endocrinology, Mayo Clinic, Rochester, Minnesota, USA.
Matthew D StrubDivision of Endocrinology, Mayo Clinic, Rochester, Minnesota, USA.
Hawley E KunzDivision of Endocrinology, Mayo Clinic, Rochester, Minnesota, USA.
Bonnie K ArendtDivision of Endocrinology, Mayo Clinic, Rochester, Minnesota, USA.
Surendra DasariDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
Scott M EbertDivision of Endocrinology, Mayo Clinic, Rochester, Minnesota, USA.
Christopher M AdamsDivision of Endocrinology, Mayo Clinic, Rochester, Minnesota, USA.
Ian R LanzaDivision of Endocrinology, Mayo Clinic, Rochester, Minnesota, USA.ORCID https://orcid.org/0000-0002-9858-3384
Mayo Clinic · USUniversity of Iowa · USConcordia University Wisconsin · USMayo Clinic in Florida · US

Funding

Enhancing Adaptations to ExerciseR01AG054454 · NIA · MAYO CLINIC ROCHESTER · PI LANZA, IAN R · 2017 to 2022
$3.3M
Novel Signaling Pathways Underlying Skeletal Muscle AtrophyR01AG060637 · NIA · UNIVERSITY OF IOWA · PI ADAMS, CHRISTOPHER M · 2018 to 2022
$2.6M
Molecular pathogenesis of skeletal muscle atrophyR01AR071762 · NIAMS · UNIVERSITY OF IOWA · PI ADAMS, CHRISTOPHER M · 2017 to 2021
$2.4M
Development of Novel Small Molecule Therapies for Skeletal Muscle AtrophyR44AG047684 · NIA · EMMYON, INC. · PI ADAMS, CHRISTOPHER M, EBERT, SCOTT MATTHEW · 2018 to 2019
$1.5M
Discovery of Novel Pharmaceutical Agents for Skeletal Muscle AtrophyR44AR069400 · NIAMS · EMMYON, INC. · PI ADAMS, CHRISTOPHER M, EBERT, SCOTT MATTHEW · 2020 to 2021
$1.5M
NIAMS NIH HHS NIAMS R01 AR071762NIAMS NIH HHS NIAMS R44 AR069400NIAMS NIH HHS R01 AR071762NIAMS NIH HHS R44 AR069400NIA NIH HHS NIA R01 AG054454NIA NIH HHS NIA R01 AG060637NIA NIH HHS NIA R44 AG047684NIA NIH HHS R01 AG054454NIA NIH HHS R01 AG060637NIA NIH HHS R44 AG047684
6 · The paper itself

Abstract

The loss of skeletal muscle mass during aging is a significant health concern linked to adverse outcomes in older individuals. Understanding the molecular basis of age-related muscle loss is crucial for developing strategies to combat this debilitating condition. Long noncoding RNAs (lncRNAs) are a largely uncharacterized class of biomolecules that have been implicated in cellular homeostasis and dysfunction across a many tissues and cell types. To identify lncRNAs that might contribute to skeletal muscle aging, we screened for lncRNAs whose expression was altered in vastus lateralis muscle from older compared to young adults. We identified FRAIL1 as an aging-induced lncRNA with high abundance in human skeletal muscle. In healthy young and older adults, skeletal muscle FRAIL1 was increased with age in conjunction with lower muscle function. Forced expression of FRAIL1 in mouse tibialis anterior muscle elicits a dose-dependent reduction in skeletal muscle fiber size that is independent of changes in muscle fiber type. Furthermore, this reduction in muscle size is dependent on an intact region of FRAIL1 that is highly conserved across non-human primates. Unbiased transcriptional and proteomic profiling of the effects of FRAIL1 expression in mouse skeletal muscle revealed widespread changes in mRNA and protein abundance that recapitulate age-related changes in pathways and processes that are known to be altered in aging skeletal muscle. Taken together, these findings shed light on the intricate molecular mechanisms underlying skeletal muscle aging and implicate FRAIL1 in age-related skeletal muscle phenotypes.

Indexed as

RNA, Long NoncodingAgedAgingAnimalsHumansMiceMuscle Fibers, SkeletalMuscle, SkeletalProteomicsRNA, Long NoncodingaginglncRNAskeletal muscle

Identifiers

PMID38297807
PMCPMC11019130
OpenAlexW4391446411

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.